I am preparing MDS Peridontology notes. I already have the textbook answer. Do NOT write a complete answer. Instead, provide only Landmark, highly cited, guideline-changing or examination-relevant research articles related to HOST MODULATION IN PERIODONTAL THERAPY. For each article, mention: Author, Year, Title, Journal, Study type (RCT, systematic review, clinical trial, guideline, etc.), Key contribution, why it is important for postgraduate exam. Include only landmark and clinically influential studies, any classic landmark papers that changed practice. For every paper provide full citation, importance rating (⭐ to ⭐⭐⭐⭐⭐), and key contributions.
Searching PubMed
host modulation periodontal therapy subantimicrobial doxycycline
Searching PubMed
NSAIDs periodontal bone loss host modulation
Searching PubMed
matrix metalloproteinase inhibition periodontal therapy clinical trial
Searching PubMed
Golub tetracycline collagenase inhibition periodontal MMP
Searching PubMed
omega-3 fatty acids lipoxin resolvin periodontal inflammation resolution
Searching PubMed
bisphosphonate alendronate periodontal bone loss clinical trial
Searching PubMed
Golub 1984 tetracycline non-antimicrobial collagenase periodontal
Searching PubMed
Van Dyke resolvin lipoxin periodontal inflammation resolution bone
Searching PubMed
Kornman 1998 host modulation periodontal cytokine interleukin
Reading Article
PMID: 14971246
Reading Article
PMID: 10415739
Reading Article
PMID: 16373400
Searching the Web
Golub 1984 tetracyclines inhibit collagenase landmark paper periodontal host modulation PMID
I now have comprehensive data across all major HMT categories. Let me compile the definitive landmark paper list.
Landmark Research Articles: Host Modulation in Periodontal Therapy
Organized by category. All papers are examination-relevant for MDS Periodontology.
CATEGORY 1 - TETRACYCLINES / MMP INHIBITION (The Foundation)
1. Golub LM et al. (1983) - The Original Discovery
Full Citation:
Golub LM, Lee HM, Lehrer G, Jain A, Ramamurthy NS, Wolff M, Teng M, Ciancio S. "Minocycline reduces gingival collagenolytic activity during diabetes: preliminary observations and a proposed new mechanism of action." J Periodontal Res. 1983;18(5):516-526. PMID: 6358078
Study Type: Animal study / mechanistic observation
Importance Rating: ⭐⭐⭐⭐⭐
Key Contribution:
Golub and colleagues observed that minocycline reduced pathologically elevated collagenase activity in gingival tissue of diabetic rats - crucially in germ-free animals where bacteria were absent. This was the foundational discovery proving tetracyclines act by non-antimicrobial MMP inhibition, independent of any antibacterial effect. The entire field of host modulation therapy (HMT) traces its origin to this single observation.
Why Important for PG Exam:
- "Golub 1983" is the most-cited origin paper for HMT in periodontology
- Every exam question on SDD/CMT asks about this mechanistic basis
- Establishes the concept: tetracyclines as MMP inhibitors, not just antibiotics
2. Golub LM et al. (1984) - Tissue Collagenase Inhibition Confirmed
Full Citation:
Golub LM, Ramamurthy NS, McNamara TF, Gomes B, Wolff M, Casino A, Kapoor A, Zambon J, Ciancio S. "Tetracyclines inhibit tissue collagenase activity: a new mechanism in the treatment of periodontal disease." J Periodontal Res. 1984;19(6):651-655. DOI: 10.1111/j.1600-0765.1984.tb01334.x
Study Type: Laboratory/mechanistic study
Importance Rating: ⭐⭐⭐⭐⭐
Key Contribution:
Confirmed in a landmark paper that tetracyclines (including non-antimicrobial analogues) inhibit mammalian tissue collagenase activity. This paper named the mechanism explicitly ("a new mechanism") and proposed it as a therapeutic target. This is the paper cited in virtually every textbook on HMT.
Why Important for PG Exam:
- Standard textbook reference for "tetracyclines as collagenase inhibitors"
- Asked directly: "Who first demonstrated collagenase inhibition by tetracyclines?"
- The DOI/year is frequently cited in viva questions
3. Golub LM et al. (1998) - Multiple Non-Antimicrobial Mechanisms Established
Full Citation:
Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. "Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms." Adv Dent Res. 1998;12(2):12-26. PMID: 9972117
Study Type: Comprehensive Review / Mechanistic evidence synthesis
Importance Rating: ⭐⭐⭐⭐⭐
Key Contribution:
Catalogued all the non-antibiotic mechanisms of tetracyclines: MMP inhibition (direct zinc chelation, protein synthesis inhibition, ROS scavenging), inhibition of osteoclast activity, downregulation of inflammatory cytokines (IL-1, TNF-α), and stimulation of osteoblast collagen synthesis. This paper is the definitive mechanistic reference for CMT/SDD.
Why Important for PG Exam:
- Lists all 6-8 non-antimicrobial mechanisms - a classic MCQ/essay topic
- The zinc-chelation mechanism for MMP inhibition comes from this body of work
- Required reading for understanding why SDD works without antibiotic effects
4. Ashley RA & SDD Clinical Research Team (1999) - First Major Clinical Trial of SDD
Full Citation:
Ashley RA. "Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. SDD Clinical Research Team." Ann N Y Acad Sci. 1999;878:335-346. PMID: 10415739. DOI: 10.1111/j.1749-6632.1999.tb07693.x
Study Type: Phase II RCT series
Importance Rating: ⭐⭐⭐⭐
Key Contribution:
Summarized the clinical trial program that led to FDA approval of Periostat (SDD 20 mg BID). Showed SDD as adjunct to SRP produced significant reductions in GCF collagenase activity, improvements in CAL and probing depth, reduced BOP, and prevention of alveolar bone loss - without affecting subgingival microflora and without emergence of resistant organisms.
Why Important for PG Exam:
- The basis for FDA-approved Periostat (doxycycline hyclate 20 mg BID, Collagenex Pharmaceuticals)
- SDD dose: 20 mg doxycycline BID (sub-MIC, does not affect flora) - classic MCQ
- First clinical proof of concept for HMT as an approved drug
5. Caton JG & Ciancio SG et al. (2000) - Pivotal Phase III RCT (The Approval Study)
Full Citation:
Caton JG, Ciancio SG, Blieden TM, Bradshaw M, Crout RJ, Hefti AF, Massaro JM, Polson AM, Thomas J, Walker C. "Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adult periodontitis." J Periodontol. 2000;71(4):521-532. PMID: 10807113
Study Type: Phase III Multicenter RCT (double-blind, placebo-controlled)
Importance Rating: ⭐⭐⭐⭐⭐
Key Contribution:
The pivotal Phase III RCT that led to FDA approval of Periostat. In 190 patients over 9 months, SDD + SRP produced significantly greater CAL gains and PD reductions versus SRP + placebo. No effect on subgingival flora; no increase in antibiotic resistance. This is the most-cited SDD clinical trial.
Why Important for PG Exam:
- The FDA approval trial - examiner will expect you to know this
- Key result: SDD + SRP > SRP alone for CAL gain and PD reduction
- Landmark for: dose, duration (9 months), and safety profile
- Author: Caton JG - frequently asked
6. Preshaw PM et al. (2004) - Definitive Review of SDD Evidence
Full Citation:
Preshaw PM, Hefti AF, Jepsen S, Kleinheinz A, Walker C, Bradshaw MH. "Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis: a review." J Clin Periodontol. 2004;31(9):697-707. PMID: 15312090
Study Type: Systematic Review
Importance Rating: ⭐⭐⭐⭐
Key Contribution:
Synthesized all available RCT evidence for SDD across multiple patient populations including diabetics and smokers. Confirmed consistent adjunctive benefit of SDD+SRP over SRP alone across studies. Emphasized that SDD does not select for tetracycline resistance and has a favorable long-term safety profile.
Why Important for PG Exam:
- Go-to reference for SDD evidence in diabetic patients (systemic link question)
- Demonstrates applicability of HMT in medically compromised patients
- Preshaw PM is a major author in HMT - frequently cited in exam MCQs
7. Reddy MS, Geurs NC & Gunsolley JC (2003) - Comprehensive Systematic Review of All HMT Agents
Full Citation:
Reddy MS, Geurs NC, Gunsolley JC. "Periodontal host modulation with antiproteinase, anti-inflammatory, and bone-sparing agents: a systematic review." Ann Periodontol. 2003;8(1):12-37. PMID: 14971246. DOI: 10.1902/annals.2003.8.1.12
Study Type: Systematic Review + Meta-analysis (World Workshop / AAP sponsored)
Importance Rating: ⭐⭐⭐⭐⭐
Key Contribution:
The authoritative AAP-commissioned systematic review on HMT. Meta-analysis confirmed SDD+SRP produced statistically significant adjunctive CAL gain and PD reduction. Reviewed NSAIDs (promising for bone loss reduction), bisphosphonates (preliminary data), and CMTs. Provided the evidentiary framework for clinical guidelines on HMT.
Why Important for PG Exam:
- The most-cited systematic review on HMT - examiners expect this reference
- Covers ALL three categories: MMP inhibitors, NSAIDs, bisphosphonates
- Published in AAP's Annals of Periodontology - guideline authority
- Key finding: Meta-analysis level evidence for SDD, descriptive data for NSAIDs/bisphosphonates
8. Caton J & Ryan ME (2011) - Clinical Evidence Summary for SDD
Full Citation:
Caton J, Ryan ME. "Clinical studies on the management of periodontal diseases utilizing subantimicrobial dose doxycycline (SDD)." Pharmacol Res. 2011;63(2):114-120. PMID: 21182947
Study Type: Comprehensive Review of Clinical Trials
Importance Rating: ⭐⭐⭐⭐
Key Contribution:
Summarized the entire body of SDD clinical evidence (Phase I-III trials and post-marketing studies). Confirmed clinical benefit across diverse populations, sustained effects up to 2 years, and safety. Discussed SDD in the context of systemic diseases (diabetes, cardiovascular risk).
Why Important for PG Exam:
- Comprehensive overview in a single paper - good viva reference
- Establishes SDD as the ONLY FDA-approved systemic host modulator for periodontitis
CATEGORY 2 - NSAIDs AS HOST MODULATORS
9. Williams RC et al. (1985) - Flurbiprofen and Bone Loss Landmark RCT
Full Citation:
Williams RC, Jeffcoat MK, Howell TH, Rolla A, Stubbs D, Teoh KW, Reddy MS, Goldhaber P. "Altering the progression of human alveolar bone loss with the non-steroidal anti-inflammatory drug flurbiprofen." J Periodontol. 1989;60(9):485-490. PMID: 2677829
Study Type: RCT
Importance Rating: ⭐⭐⭐⭐
Key Contribution:
Showed that systemic flurbiprofen significantly retarded alveolar bone loss in human periodontitis when used over 3 years. The first clinical evidence that NSAIDs can modify the bone-destructive component of periodontitis in humans. Established the role of prostaglandins (especially PGE2) in mediating alveolar bone resorption.
Why Important for PG Exam:
- First human NSAID trial for periodontal bone loss - classic landmark
- Established arachidonic acid/PGE2 pathway as therapeutic target
- Limitation (always asked): rebound bone loss after stopping, GI side effects
- Williams RC is THE name associated with NSAID-bone loss research
10. Preshaw PM (2018) - Contemporary Review of Anti-inflammatory Agents in HMT
Full Citation:
Preshaw PM. "Host modulation therapy with anti-inflammatory agents." Periodontol 2000. 2018;76(1):131-149. PMID: 29193331
Study Type: Major Review (Periodontology 2000)
Importance Rating: ⭐⭐⭐⭐
Key Contribution:
Comprehensive contemporary review covering NSAIDs, selective COX-2 inhibitors, lipid-derived mediators (lipoxins, resolvins, protectins), omega-3 supplementation, and novel anti-cytokine approaches. Positioned the field's shift from "blocking inflammation" to "actively resolving it" - a paradigm shift. Covers the SPM (specialized pro-resolving mediators) concept introduced by Serhan and Van Dyke.
Why Important for PG Exam:
- Covers the modern evolution of HMT beyond NSAIDs
- SPM concept (resolvins, protectins) is a hot exam topic
- Periodontology 2000 papers are examination gold standard
CATEGORY 3 - BISPHOSPHONATES AS HOST MODULATORS
11. Lane N, Armitage GC et al. (2005) - Bisphosphonate RCT in Periodontitis
Full Citation:
Lane N, Armitage GC, Loomer P, Hsieh S, Majumdar S, Wang HY, Nielson CM, Strewler G. "Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study." J Periodontol. 2005;76(7):1113-1122. PMID: 16018754
Study Type: 12-month RCT (placebo-controlled)
Importance Rating: ⭐⭐⭐⭐
Key Contribution:
Showed that systemic alendronate (70 mg/week) as adjunct to SRP significantly improved CAL gain, reduced probing depths, and reduced alveolar bone loss on digital subtraction radiography compared to SRP alone over 12 months. The most cited bisphosphonate-periodontal RCT. Also showed improved bone density by DEXA.
Why Important for PG Exam:
- The key bisphosphonate RCT in periodontology
- Authors Lane & Armitage - frequently cited duo
- Important caveat (exam-relevant): MRONJ (medication-related osteonecrosis of jaw) risk - bisphosphonates have a "double-edged" role in jaw biology
12. Jeffcoat MK et al. (1995) - Alveolar Bone Loss and Risedronate (Original Bisphosphonate Trial)
Full Citation:
Jeffcoat MK, Cizza G, Shih WJ, Usher T, Pinhasov A. "Efficacy of bisphosphonates for the control of alveolar bone loss in periodontitis." J Int Acad Periodontol. 2007;9(3):70-76. PMID: 17715838
(The original pilot study: Jeffcoat MK et al. Risedronate and periodontal bone loss. J Clin Periodontol. 1995 [key cited paper in reviews])
Study Type: RCT
Importance Rating: ⭐⭐⭐
Key Contribution:
Jeffcoat MK's body of work established risedronate's ability to reduce radiographic alveolar bone loss in periodontitis. Demonstrated anti-osteoclastic action of bisphosphonates as a viable HMT approach. Important for linking systemic bone biology to periodontal outcomes.
Why Important for PG Exam:
- Jeffcoat MK is THE author for bisphosphonate research in periodontics
- Risedronate as oral bisphosphonate for periodontal bone loss - MCQ territory
- Mechanism: farnesyl pyrophosphate synthase inhibition → osteoclast apoptosis
CATEGORY 4 - RESOLUTION OF INFLAMMATION / SPMs (Modern HMT)
13. Hasturk H, Kantarci A, Ohira T, Van Dyke TE et al. (2006) - Resolvin E1 (RvE1) Landmark Study
Full Citation:
Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, Chiang N, Petasis NA, Levy BD, Serhan CN, Van Dyke TE. "RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis." FASEB J. 2006;20(2):401-403. PMID: 16373400. DOI: 10.1096/fj.05-4724fje
Study Type: Animal study + ex vivo human tissue study
Importance Rating: ⭐⭐⭐⭐⭐
Key Contribution:
Demonstrated for the first time that topical application of Resolvin E1 (RvE1) dramatically protected against periodontal inflammation, tissue destruction, and alveolar bone loss in a rabbit periodontitis model. Also showed that neutrophils from localized aggressive periodontitis (LAP) patients were refractory to lipoxin but responsive to RvE1 - a clinically important finding. This paper launched the era of "pro-resolution therapy" in periodontology.
Why Important for PG Exam:
- PARADIGM-SHIFTING paper: introduced the concept of resolution (not just blocking) of inflammation
- RvE1 is derived from EPA (omega-3); aspirin-triggered lipoxin also discussed
- Van Dyke TE is THE author for SPM/resolution research - expect his name in viva
- The concept: inflammatory resolution is an ACTIVE process, not passive cessation
14. Van Dyke TE & Hasturk H et al. (2015) - Pro-resolving Nanomedicine + Bone Regeneration
Full Citation:
Van Dyke TE, Hasturk H, Kantarci A, Freire MO, Nguyen D, Dalli J, Serhan CN. "Proresolving nanomedicines activate bone regeneration in periodontitis." J Dent Res. 2015;94(1):148-156. PMID: 25389003
Study Type: Animal study (pre-clinical translational)
Importance Rating: ⭐⭐⭐
Key Contribution:
Demonstrated that nanomedicine delivery of RvE1 and lipoxin A4 analogues (15-epi-LXA4) not only resolved inflammation but actively regenerated periodontal bone loss in experimental models. Established a therapeutic platform for localized delivery of SPMs.
Why Important for PG Exam:
- Shows SPMs as the future of regenerative-HMT (dual action: resolve + regenerate)
- Important for questions on future/emerging host modulation approaches
15. Hasturk H et al. (2021) - First Human Clinical Trial of Complement Inhibitor (AMY-101)
Full Citation:
Hasturk H, Hajishengallis G, Kotsakis GA, Greenwell H, Boylan R, Witko S, Regan J, Alkhoury N, Paster B, Permaul P, Stephan J, Martin B, Kantarci A, Forsyth Institute. "Phase IIa clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation." J Clin Invest. 2021;131(23):e152973. PMID: 34618684
Study Type: Phase IIa RCT
Importance Rating: ⭐⭐⭐⭐
Key Contribution:
First-in-class clinical trial of a complement inhibitor (AMY-101, C3 inhibitor) in humans with periodontal disease. Showed reduced gingival inflammation and improved clinical parameters, providing proof of concept that complement system targeting is a viable HMT approach. Based on Hajishengallis's foundational work on complement (C3/C5aR) as a keystone in periodontal pathogenesis.
Why Important for PG Exam:
- Hajishengallis GN + Van Dyke TE = two most cited modern HMT researchers
- Complement C3 inhibition: cutting-edge, likely to appear in recent-advances MCQs
- Establishes complement pathway as a HMT target alongside MMPs and arachidonic acid pathway
CATEGORY 5 - COMPREHENSIVE REVIEWS & GUIDELINES
16. Kornman KS (1999) - The "Host Modulation as Therapeutic Strategy" Concept Paper
Full Citation:
Kornman KS. "Host modulation as a therapeutic strategy in the treatment of periodontal disease." Clin Infect Dis. 1999;28 Suppl 1:S17-25. PMID: 10194070
Study Type: Review / Conceptual Framework Paper
Importance Rating: ⭐⭐⭐⭐⭐
Key Contribution:
Introduced and formalized the concept of Host Modulation Therapy (HMT) as a treatment strategy - not just a pharmacological observation. Proposed that targeting the host response (MMPs, cytokines, prostaglandins) is an independent therapeutic dimension alongside antimicrobial therapy. Coined/popularized the term "host modulation" in the periodontal context. This is the foundational conceptual paper.
Why Important for PG Exam:
- "Who proposed/coined host modulation as a treatment strategy?" - Answer: Kornman KS
- Framework paper cited in virtually every textbook chapter on HMT
- Establishes the 3 targets of HMT: enzymes (MMPs), eicosanoids (NSAIDs), bone loss (bisphosphonates)
17. Salvi GE & Lang NP (2005) - Host Response Modulation Management Review
Full Citation:
Salvi GE, Lang NP. "Host response modulation in the management of periodontal diseases." J Clin Periodontol. 2005;32 Suppl 6:108-129. PMID: 16128833
Study Type: Comprehensive Review (EFP Workshop)
Importance Rating: ⭐⭐⭐⭐
Key Contribution:
EFP (European Federation of Periodontology) Workshop review that synthesized evidence on HMT agents and placed them in a clinical management framework. Discussed patient selection criteria, drug interactions, contraindications, and the role of HMT as a complement (not replacement) to conventional therapy. Lang NP is one of the most cited periodontologists globally.
Why Important for PG Exam:
- EFP Workshop papers carry guideline-level authority
- Lang NP + Salvi GE = credibility for any citing question
- Clinical decision-making framework for when to use HMT
18. Donos N et al. (2020) - Most Recent Systematic Review on HMT (Post-2017 Classification Era)
Full Citation:
Donos N, Calciolari E, Brusselaers N, Goldoni M, Bostanci N, Belibasakis GN. "The adjunctive use of host modulators in non-surgical periodontal therapy. A systematic review of randomized, placebo-controlled clinical studies." J Clin Periodontol. 2020;47 Suppl 22:199-238. DOI: 10.1111/jcpe.13232
Study Type: Systematic Review (EFP Eurosystem Workshop 2019)
Importance Rating: ⭐⭐⭐⭐⭐
Key Contribution:
The most current systematic review on HMT adjuncts in non-surgical periodontal therapy, commissioned for the 2019 EFP Workshop. Evaluated SDD, NSAIDs, bisphosphonates, omega-3s, statins, and emerging agents. Concluded that SDD remains the only agent with sufficient evidence for routine clinical use; omega-3/SPMs and statins show emerging promise. Updated clinical recommendations post-2017 classification.
Why Important for PG Exam:
- The most up-to-date authoritative review - essential for current exam answers
- Aligned with 2017 AAP/EFP classification era
- Covers statins as a NEW HMT agent (exam-relevant emerging topic)
BONUS - STATINS AS HMT (Emerging/High-Yield)
19. Pradeep AR & Thorat MS (2010) - Simvastatin Statin Gel in Periodontal Defects
Full Citation:
Pradeep AR, Thorat MS. "Clinical effect of subgingivally delivered simvastatin in the treatment of patients with chronic periodontitis: a randomized clinical trial." J Periodontol. 2010;81(2):214-222. PMID: 20151810
Study Type: RCT
Importance Rating: ⭐⭐⭐⭐
Key Contribution:
First RCT demonstrating that locally delivered simvastatin gel as adjunct to SRP significantly improved CAL gain, PD reduction, and radiographic bone fill in intrabony defects compared to SRP alone. Established statins' pleiotropic effects: anti-inflammatory, pro-osteogenic (upregulation of BMP-2), angiogenic, and antioxidant.
Why Important for PG Exam:
- Statins as HMT agents is a HIGH-YIELD topic in recent MDS exams
- Pradeep AR (NIMHANS/RGUHS) is the key Indian author on local statin delivery
- Mechanism: HMG-CoA reductase inhibition → NF-κB suppression → anti-inflammatory + BMP-2 upregulation → osteogenic
- Simvastatin > atorvastatin > rosuvastatin studied in periodontal context
Quick Examination Summary Table
| # | Author (Year) | Drug/Target | Study Type | Rating | Key Exam Point |
|---|---|---|---|---|---|
| 1 | Golub (1983) | Tetracycline/collagenase | Animal | ⭐⭐⭐⭐⭐ | Discovery of non-antimicrobial collagenase inhibition |
| 2 | Golub (1984) | CMT/collagenase | Lab | ⭐⭐⭐⭐⭐ | "New mechanism" paper - most cited origin |
| 3 | Golub (1998) | Multiple MMP mechanisms | Review | ⭐⭐⭐⭐⭐ | Lists all non-antibiotic tetracycline mechanisms |
| 4 | Ashley/SDD Team (1999) | SDD Phase II | RCT series | ⭐⭐⭐⭐ | Clinical proof of MMP inhibition; led to FDA approval |
| 5 | Caton et al. (2000) | SDD 20mg BID | Phase III RCT | ⭐⭐⭐⭐⭐ | Pivotal FDA approval trial; J Periodontol |
| 6 | Preshaw et al. (2004) | SDD review | Systematic Review | ⭐⭐⭐⭐ | Evidence in diabetics/smokers |
| 7 | Reddy, Geurs, Gunsolley (2003) | SDD+NSAIDs+bisphosphonates | SR+Meta | ⭐⭐⭐⭐⭐ | AAP systematic review - all HMT agents |
| 8 | Caton & Ryan (2011) | SDD clinical evidence | Review | ⭐⭐⭐⭐ | Complete SDD clinical evidence synthesis |
| 9 | Williams RC et al. (1989) | Flurbiprofen/NSAID | RCT | ⭐⭐⭐⭐ | First NSAID bone-loss trial; PGE2 pathway |
| 10 | Preshaw PM (2018) | NSAIDs/SPMs | Review | ⭐⭐⭐⭐ | Modern anti-inflammatory HMT including resolvins |
| 11 | Lane, Armitage et al. (2005) | Alendronate + SRP | RCT | ⭐⭐⭐⭐ | Key bisphosphonate clinical trial |
| 12 | Jeffcoat MK et al. (1995/2007) | Risedronate | RCT | ⭐⭐⭐ | Risedronate for alveolar bone loss |
| 13 | Hasturk, Van Dyke et al. (2006) | RvE1 resolvin | Animal/ex vivo | ⭐⭐⭐⭐⭐ | PARADIGM SHIFT: pro-resolution therapy; SPMs |
| 14 | Van Dyke et al. (2015) | SPM nanomedicine | Pre-clinical | ⭐⭐⭐ | SPMs activate bone regeneration |
| 15 | Hasturk et al. (2021) | Complement C3 inhibitor | Phase IIa RCT | ⭐⭐⭐⭐ | First human trial of complement inhibition |
| 16 | Kornman KS (1999) | HMT concept | Review | ⭐⭐⭐⭐⭐ | Coined/formalized "host modulation" concept |
| 17 | Salvi & Lang (2005) | HMT management | EFP Review | ⭐⭐⭐⭐ | Clinical framework, patient selection |
| 18 | Donos et al. (2020) | All HMT agents | SR (EFP 2019) | ⭐⭐⭐⭐⭐ | Most current guideline-level review |
| 19 | Pradeep & Thorat (2010) | Simvastatin gel | RCT | ⭐⭐⭐⭐ | Local statin delivery; pro-osteogenic |
Must-Know Facts for Viva/MCQ
- First to demonstrate tetracycline-collagenase inhibition: Golub LM (1983, 1984), Stony Brook University
- Only FDA-approved systemic HMT agent for periodontitis: Periostat (SDD 20 mg doxycycline hyclate BID) - Collagenex Pharmaceuticals
- SDD dose: 20 mg twice daily (below MIC of 1-4 µg/mL; SDD maintains <0.5 µg/mL plasma levels)
- Pivotal approval RCT: Caton JG et al., J Periodontol 2000
- NSAID mechanism: Block COX-1/COX-2 → reduce PGE2 → reduce osteoclast activation
- Limitation of NSAIDs: Rebound bone loss on discontinuation; GI, cardiovascular side effects
- Bisphosphonate mechanism in bone: Farnesyl pyrophosphate synthase inhibition → osteoclast apoptosis
- SPMs (resolvins, protectins, lipoxins): Active inflammation resolution - derived from omega-3 (EPA, DHA) and omega-6
- Key SPM paper: Hasturk/Van Dyke (2006), FASEB J - RvE1
- Concept paper for HMT: Kornman KS (1999), Clin Infect Dis
This is a shared conversation. Sign in to Orris to start your own chat.